MP
ALDX icon

Mangrove Partners’s Aldeyra Therapeutics ALDX Stock Holding History

Mangrove Partners’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-707,746
Closed -$5.87M – 73
2018
Q4 		$5.87M Hold
707,746
– – 0.78% 29
2018
Q3 		$9.77M Buy
707,746
+273,402
+63% +$2.22M 0.62% 18
2018
Q2 		$3.45M Buy
434,344
+110,325
+34% +$880K 0.22% 27
2018
Q1 		$2.43M Buy
324,019
+159,635
+97% +$1.21M 0.16% 30
2017
Q4 		$1.12M Buy
+164,384
New +$1.08M 0.15% 32

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mangrove Partners's ALDX Position: Q1 2019 in Review

Mangrove Partners sold out of Aldeyra Therapeutics (ALDX) in Q1 2019, closing a stake of 707,746 shares — an estimated $5.87M sold.

Mangrove Partners first reported a position in ALDX in Q4 2017 and held it in 5 quarters. The position peaked at $9.77M in Q3 2018. 79 funds tracked by Wall St. Rank hold ALDX as of Q1 2019.

  • Mangrove Partners reported no remaining Aldeyra Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Mangrove Partners sold 707,746 Aldeyra Therapeutics shares in Q1 2019, an estimated $5.87M.
  • Mangrove Partners first reported a position in Aldeyra Therapeutics in Q4 2017 and held it in 5 quarters.
  • Mangrove Partners's Aldeyra Therapeutics position peaked at $9.77M in Q3 2018.
  • 79 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2019.

Based on Mangrove Partners's 13F filing for Q1 2019, filed 15 May 2019.